These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox. Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899 [TBL] [Abstract][Full Text] [Related]
4. A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity. Porter JB; Faherty A; Stallibrass L; Brookman L; Hassan I; Howes C Ann N Y Acad Sci; 1998 Jun; 850():483-7. PubMed ID: 9668591 [No Abstract] [Full Text] [Related]
5. [Long-term follow-up and bone imaging in acquired osteochondrodysplasia in a female patient with thalassemia and desferrioxamine hypersensitivity]. Mangiagli A; De Sanctis V; Campisi S; Di Silvestro G; Urso L Minerva Pediatr; 2000 Apr; 52(4):235-41. PubMed ID: 11995208 [TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Tanner MA; Galanello R; Dessi C; Smith GC; Westwood MA; Agus A; Roughton M; Assomull R; Nair SV; Walker JM; Pennell DJ Circulation; 2007 Apr; 115(14):1876-84. PubMed ID: 17372174 [TBL] [Abstract][Full Text] [Related]
7. Compliance and satisfaction with deferasirox (Exjade®) compared with deferoxamine in patients with transfusion-dependent beta-thalassemia. Haghpanah S; Zarei T; Zahedi Z; Karimi M Hematology; 2014 Jun; 19(4):187-91. PubMed ID: 24074344 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Elalfy MS; Adly AM; Wali Y; Tony S; Samir A; Elhenawy YI Eur J Haematol; 2015 Nov; 95(5):411-20. PubMed ID: 25600572 [TBL] [Abstract][Full Text] [Related]
9. The effect of combined therapy with deferoxamine and deferiprone on serum ferritin level of beta-thalassemic patients. Mirbehbahani N; Jahazi A; Rahim Abad HH Hematology; 2012 May; 17(3):183-6. PubMed ID: 22664119 [TBL] [Abstract][Full Text] [Related]
10. Multimodal imaging in a case of deferoxamine-induced maculopathy. Gelman R; Kiss S; Tsang SH Retin Cases Brief Rep; 2014; 8(4):306-9. PubMed ID: 25372534 [TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of combined iron-chelation therapy with deferoxamine and deferiprone. Alymara V; Bourantas D; Chaidos A; Bouranta P; Gouva M; Vassou A; Tzouvara E; Bourantas KL Hematol J; 2004; 5(6):475-9. PubMed ID: 15570288 [TBL] [Abstract][Full Text] [Related]
12. Effect of iron chelator desferrioxamine on serum zinc levels in patients with beta thalassemia major. Sultan S; Irfan SM; Kakar J; Zeeshan R Malays J Pathol; 2015 Apr; 37(1):35-8. PubMed ID: 25890611 [TBL] [Abstract][Full Text] [Related]
13. Sensorineural hearing loss in β-thalassemia patients treated with iron chelation. Osma U; Kurtoglu E; Eyigor H; Yilmaz MD; Aygener N Ear Nose Throat J; 2015 Dec; 94(12):481-5. PubMed ID: 26670754 [TBL] [Abstract][Full Text] [Related]
14. Nephrolithiasis in patients exposed to deferasirox and desferioxamine: probably an age-linked event with different effects on some renal parameters. Ricchi P; Ammirabile M; Costantini S; Spasiano A; Di Matola T; Cinque P; Casale M; Filosa A; Prossomariti L Ann Hematol; 2014 Mar; 93(3):525-7. PubMed ID: 23807253 [No Abstract] [Full Text] [Related]
15. Incidence of deferasirox-associated renal tubular dysfunction in children and young adults with beta-thalassaemia. Dee CM; Cheuk DK; Ha SY; Chiang AK; Chan GC Br J Haematol; 2014 Nov; 167(3):434-6. PubMed ID: 24989901 [No Abstract] [Full Text] [Related]
16. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major. Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174 [TBL] [Abstract][Full Text] [Related]
18. Iron-chelation therapy with oral chelators in patients with thalassemia major. Uygun V; Kurtoglu E Hematology; 2013 Jan; 18(1):50-5. PubMed ID: 23321010 [TBL] [Abstract][Full Text] [Related]
19. [Monitoring of the harmful effects of iron on the hearts of patients with beta-thalassemia major, using non-invasive cardiological technics]. Pisano GF; Binaghi F; Putzu ML; Bragotti R; Manconi E; Urgu G; Pitzus F Boll Soc Ital Cardiol; 1981; 26(10):1227-33. PubMed ID: 7349145 [No Abstract] [Full Text] [Related]
20. Efficacy and safety of deferasirox compared with deferoxamine in sickle cell disease: two-year results including pharmacokinetics and concomitant hydroxyurea. Vichinsky E; Torres M; Minniti CP; Barrette S; Habr D; Zhang Y; Files B; Am J Hematol; 2013 Dec; 88(12):1068-73. PubMed ID: 23946212 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]